Advertisement
CYTK vs NXTC
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a Buy and NXTC is a Buy.
CYTK's RSI Oscillator ascending out of oversold territory
The RSI Indicator for CYTK moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 22 of the 24 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for CYTK just turned positive on October 13, 2026. Looking at past instances where CYTK's MACD turned positive, the stock continued to rise in 41 of 57 cases over the following month. The odds of a continued upward trend are 72%.
Following a +3.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYTK advanced for three days, in 215 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
CYTK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CYTK as a result. In 84 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The 50-day moving average for CYTK moved below the 200-day moving average on October 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYTK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for CYTK entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. CYTK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 76 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYTK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CYTK's P/B Ratio (-48.666) is slightly lower than the industry average of (3.037). P/E Ratio (-8.411) is within average values for comparable stocks, (-1.223). CYTK's Projected Growth (PEG Ratio) (82.230) is slightly higher than the industry average of (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (128.205) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Aroon Indicator for NXTC shows an upward move is likely
NXTC's Aroon Indicator triggered a bullish signal on October 21, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 101 similar instances where the Aroon Indicator showed a similar pattern. In 98 of the 101 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +10.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where NXTC advanced for three days, in 188 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for NXTC moved out of overbought territory on October 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 24 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Momentum Indicator moved below the 0 level on October 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NXTC as a result. In 73 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for NXTC turned negative on October 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 35 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
NXTC moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NXTC crossed bearishly below the 50-day moving average on October 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NXTC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
NXTC broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. NXTC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.969) is normal, around the industry mean (3.037). P/E Ratio (-0.631) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NXTC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CYTK | NXTC | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 79 | 84 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 93 Overvalued | 64 Fair valued | |
PROFIT vs RISK RATING 1..100 | 76 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 61 | 61 | |
P/E GROWTH RATING 1..100 | 19 | 34 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NXTC's Valuation (64) in the Biotechnology industry is in the same range as CYTK (93). This means that NXTC’s stock grew similarly to CYTK’s over the last 12 months.
CYTK's Profit vs Risk Rating (76) in the Biotechnology industry is in the same range as NXTC (100). This means that CYTK’s stock grew similarly to NXTC’s over the last 12 months.
CYTK's SMR Rating (100) in the Biotechnology industry is in the same range as NXTC (100). This means that CYTK’s stock grew similarly to NXTC’s over the last 12 months.
CYTK's Price Growth Rating (61) in the Biotechnology industry is in the same range as NXTC (61). This means that CYTK’s stock grew similarly to NXTC’s over the last 12 months.
CYTK's P/E Growth Rating (19) in the Biotechnology industry is in the same range as NXTC (34). This means that CYTK’s stock grew similarly to NXTC’s over the last 12 months.
| CYTK | NXTC | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| Stochastic ODDS (%) | 2 days ago 80% | 2 days ago 81% |
| Momentum ODDS (%) | 2 days ago 83% | 2 days ago 85% |
| MACD ODDS (%) | 2 days ago 72% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 78% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 77% | 2 days ago 86% |
| Advances ODDS (%) | 8 days ago 73% | 2 days ago 81% |
| Declines ODDS (%) | 2 days ago 78% | 6 days ago 86% |
| BollingerBands ODDS (%) | 2 days ago 76% | 2 days ago 87% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CYTK’s FA Score shows that 1 FA rating(s) are green while NXTC’s FA Score has 0 green FA rating(s).
- CYTK’s FA Score: 1 green, 4 red.
- NXTC’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CYTK’s TA Score shows that 5 TA indicator(s) are bullish while NXTC’s TA Score has 3 bullish TA indicator(s).
- CYTK’s TA Score: 5 bullish, 4 bearish.
- NXTC’s TA Score: 3 bullish, 7 bearish.
Price Growth
CYTK (@Biotechnology) experienced а -3.06% price change this week, while NXTC (@Biotechnology) price change was -7.85% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.36%. For the same industry, the average monthly price growth was -10.67%, and the average quarterly price growth was -13.51%.
Reported Earning Dates
CYTK is expected to report earnings on Nov 04, 2026.
NXTC is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (+4.36% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CYTK and
Correlation & Price change
A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with VRDN. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then VRDN could also see price increases.
| Ticker / NAME | Correlation To CYTK | 1D Price Change % | ||
|---|---|---|---|---|
| CYTK | 100% | -0.82% | ||
| VRDN - CYTK | 42% Loosely correlated | +4.34% | ||
| DARE - CYTK | 42% Loosely correlated | -0.33% | ||
| AXSM - CYTK | 41% Loosely correlated | -0.68% | ||
| BBIO - CYTK | 40% Loosely correlated | -0.60% | ||
| SRRK - CYTK | 40% Loosely correlated | +0.53% | ||
More | ||||
NXTC and
Correlation & Price change
A.I.dvisor indicates that over the last year, NXTC has been loosely correlated with JSPR. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if NXTC jumps, then JSPR could also see price increases.
| Ticker / NAME | Correlation To NXTC | 1D Price Change % | ||
|---|---|---|---|---|
| NXTC | 100% | +4.92% | ||
| JSPR - NXTC | 37% Loosely correlated | -0.90% | ||
| CYTK - NXTC | 37% Loosely correlated | -0.82% | ||
| ORMP - NXTC | 33% Poorly correlated | -1.21% | ||
| GOSS - NXTC | 32% Poorly correlated | -4.74% | ||
| TAOX - NXTC | 28% Poorly correlated | -3.63% | ||
More | ||||